Business, energy, technology, markets and global industry news from Business News Today

EGFR-mutated NSCLC

PharmaDeviceNews EGFR-mutated NSCLC
Abbisko Therapeutics and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated non-small cell lung cancer, putting safety, pneumonitis risk and treatment durability under close scrutiny. Representative image.
Pharma & Biotech

AstraZeneca adds Abbisko’s lumipodlin to expanding Tagrisso combination strategy

Discover why Abbisko and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated lung cancer.

Read More
Representative image: An oncologist discusses subcutaneous lung cancer treatment with a patient. The recent FDA approval of RYBREVANT FASPRO for EGFR-mutated NSCLC highlights a shift toward faster, chemotherapy-free options.
Pharma & Biotech

FDA clears subcutaneous RYBREVANT FASPRO for first-line EGFR+ NSCLC: What this changes for patients and providers

The U.S. Food and Drug Administration has approved Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first subcutaneous version of its bispecific EGFR-MET antibody therapy, for patients with EGFR-mutated non-small cell lung cancer (NSCLC). The approval spans all current RYBREVANT indications and is based on the Phase 3 PALOMA-3 study, which demonstrated comparable pharmacokinetics

Read More